Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells
نویسندگان
چکیده
منابع مشابه
BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) with the 17p deletion. Venetoclax has demonstrated marked activity as monotherapy as well as in combination with cytotoxic chemotherapies, B-cell receptor inhibitors, and anti-CD20 monoclonal antibodies across the spectrum of C...
متن کاملGrowth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells.
The bcl-2 gene is translocated into the Ig loci in about 80% of human follicular lymphomas and in 10% of B-type chronic lymphocytic leukemias (B-CLL), resulting in a high level of expression. We have compared the expression of bcl-2 transcripts and protein in B-CLL cells in their normal equivalent CD5+ B cells and in normal B-cell populations representative of different in vivo and in vitro sta...
متن کاملAkt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
BACKGROUND The phosphatidylinositol-3-kinase/Akt pathway has been described to be critical in the survival of chronic lymphocytic leukemia cells. In this study we analyzed the effect of two selective chemical inhibitors of Akt (Akti-1/2 and A-443654) on the survival of chronic lymphocytic leukemia cells. DESIGN AND METHODS Using cytometry we studied the cytotoxic effects of Akt inhibitors on ...
متن کاملCombination Chemotherapy of Advanced Chronic Lymphocytic Leukemia : The M - 2
1 1 10 Blood. Vol. 60. No. 5 (November). 1982 The M-2 protocol (vincristine. cyclophosphamide. BCNU. melphalan. and prednisone) was administered monthly to 63 evaluable patients with advanced chronic lymphocytic leukemia. Complete remission (absence of all clinical and bone marrow evidence of leukemia) and partial response (>50% decrease in organ enlargement and reduction of WBC count to below ...
متن کاملTargeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.
Chronic lymphocytic leukemia (CLL) is characterized by clonal accumulation of CD5(+) CD19(+) B lymphocytes that are arrested in the G(0)/G(1) phase of the cell cycle and fail to undergo apoptosis because of overexpression of the antiapoptotic B-cell CLL/lymphoma 2 (BCL-2) protein. Oncolytic viruses, such as vesicular stomatitis virus (VSV), have emerged as potential anticancer agents that selec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia & Lymphoma
سال: 2015
ISSN: 1042-8194,1029-2403
DOI: 10.3109/10428194.2015.1063141